Independent Director Director Since: 2024 Age: 61 Committee Service: Audit Science and Technology Professional Experience: President and Chief Executive Officer, Schrödinger, Inc. (2017 present), and preceded by various positions of increasing responsibility (2002 2017) Assistant Professor of Chemistry, Rutgers University (1994-2001) Education: B.S., Chemistry, University of Rochester Ph.D., Chemistry, California Institute of Technology Other Public Company Boards: Schrödinger, Inc. (2012 present) Structure Therapeutics Inc. (2019 2024) Morphic Therapeutic Inc. (2016 2019) Other Affiliations: Service on the boards of directors for private biotechnology companies, including: Nimbus Therapeutics (also co-founder); Ajax Therapeutics, Inc.; and Oak Hill Bio Ltd. Author for over 100 peer reviewed publications National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics, University of Pennsylvania The Nominating and Corporate Governance Committee and Board believe Dr. Farid is qualified to serve on the Board due to his computational and data sciences expertise and his experience as Chief Executive Officer and a director of publicly traded companies.